As an example, formulation of an IL-1β-VLP conjugate vaccine in Alum was sufficient to induce neutralizing anti-IL-1 antibodies in at least a fraction of human type II diabetes patients (Cavelti-Weder et al., 2016). The gene discussed is IL1B; the disease is type 2 diabetes mellitus.